Results 81 to 90 of about 8,581 (194)

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J. Cooper, John Gordon, Catherine A. Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews, Nicholas M. Barnes   +10 more
wiley   +1 more source

Kan psilocybin minska depressionssymtom

, 2021
Introduktion: Depression är en vanlig psykisk sjukdom som påverkar patientenslivskvalitet negativt. Symtomatisk kan depression orsaka att patienten känna sig ledsen,orolig, tom, hopplös, rastlös och ännu allvarligare kan depressiva patienter försökaeller 
Bator, Elena
core  

Psilocybin Response 806189750

, 2021
Psilocybin public submission for proposed amendments to the Poison Standards, November 2020 ACMS/ACCS meeting.
Victor Chiruta (11741927)
core   +1 more source

DECRIMINALIZES PSILOCYBIN MUSHROOMS. INITIATIVE STATUTE.

, 2019
Decriminalizes under state law the personal possession, storage, use, cultivation, manufacturing, giving away or furnishing for personal use, or consumption of psilocybin mushrooms and the hallucinogenic chemical compounds contained in them (including ...

core   +3 more sources

Structural basis for psilocybin biosynthesis

Nature Communications
Psilocybin shows significant therapeutic potential for psilocybin-assisted psychotherapy in addressing various psychiatric conditions. The biosynthetic approach promises rapid and efficient production of psilocybin.
Chunyan Meng, Wenting Guo, Chuan Xiao, Yan Wen, Xudong Zhu, Qingrong Zhang, Yuxuan Liang, Hongwei Li, Sha Xu, Yuntan Qiu, Haitao Chen, Wei-Jye Lin, Baixing Wu   +12 more
doaj   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

Psilocybin in the treatment of substance use disorder

, 2018
Review of the current knowledge and ongoing studies on psilocybin in treatment of substance use disorderSZGáltalános orvosangolegységes ...
Fridman, Alexander
core  

Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians

Journal of Eating Disorders
Background Clinical trials using psilocybin therapy to treat anorexia nervosa (AN) are currently underway. The safety and tolerability of psilocybin is of utmost importance in individuals with AN who may present unique medical vulnerabilities.
Amanda E. Downey, Anita V. Chaphekar, Joshua Woolley, Marissa Raymond-Flesch   +3 more
doaj   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?

, 2021
Psilocybin, a drug most commonly recognized as a recreational psychedelic, is quickly gaining attention as a promising therapy for an expanding range of neurological conditions, including depression, anxiety, and addiction.
William J. Gibbons Jr. (7871900), J. Andrew Jones (1529173), Brooke A. Bollinger (11606648), Philip J. O’Dell (11606645), Madeline G. McKinney (11606642)   +4 more
core   +1 more source